Hopiavuori, Blake R.
Deák, Ferenc
Wilkerson, Joseph L.
Brush, Richard S.
Rocha-Hopiavuori, Nicole A.
Hopiavuori, Austin R.
Ozan, Kathryn G.
Sullivan, Michael T.
Wren, Jonathan D.
Georgescu, Constantin
Szweda, Luke
Awasthi, Vibhudutta
Towner, Rheal
Sherry, David M.
Anderson, Robert E.
Agbaga, Martin-Paul
Funding for this research was provided by:
National Eye Institute (R01EY00871, R01EY04149, P30EY021725)
National Institute of Neurological Disorders and Stroke (R21NS090117, F31NS089358)
Reynolds Oklahoma Center on Aging (Collaborative Grant, Pre-doctoral Fellowship)
Research to Prevent Blindness (Departmental)
Presbyterian Health Foundation
Knights Templar Eye Foundation
BrightFocus Foundation
Article History
Received: 17 October 2017
Accepted: 7 November 2017
First Online: 22 November 2017
Compliance with Ethical Standards
:
: Dr. Hopiavuori, Dr. Anderson, Dr. Agbaga, and Mr. Brush have a US Patent application (US20170014365) for the use of VLC-SFA in the treatment of human disease.